GlassScriptPhysician profile
Nancy S Mckenzie
NPI 1598820615
$528.92
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $129 · 2021: $32.98.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $127.85 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $110.24 | 2019-2021 | |
| Tris Pharma INC | $60.58 | 2019 | |
| Pfizer INC. | $40.29 | 2020 | |
| Cranial Technologies, INC | $33.10 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $25.95 | 2019-2020 | |
| Neos Therapeutics, LP | $25.85 | 2019-2020 | |
| Genentech USA, INC. | $21.45 | 2019 | |
| Circassia INC. | $20.86 | 2019 | |
| Glaxosmithkline, LLC. | $18.50 | 2021 | |
| Kaleo, INC. | $18.37 | 2019 | |
| Phadia US INC. | $13.57 | 2019 | |
| Amneal Pharmaceuticals LLC | $12.31 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Mckenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.